All In Biotech

Drug Trial Radar · NCT02735070

Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold

Phase III Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold

Last checked: Nov 20, 2026Latest source record: Apr 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 366 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

366

Planned (sponsor's estimate)

Start

Sep 2016

Primary completion

Mar 2017

Study completion Mar 2017

Sponsor

Sponsor type
Industry
Collaborators
Techtrials Pesquisa e Tecnologia Ltda; Pharmagenix
First posted
Apr 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the non-inferiority of Coristina® d in the symptomatic treatment of the common cold compared to Resfenol® comparator.

Conditions

  • Cold

Interventions

  • ResfenolDrug

    Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.

  • Coristina dDrug

    Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Global Evaluation from 1 to 3 days after last doseTime frame: From 1 to 3 days after the last dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.